BJH - volume 8, issue 2, march 2017
M.C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, K. Fostier MD, A. Kentos MD, PhD, P. Mineur MD, M. Vaes MD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, P. Vlummens MD, K.L. Wu MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)
The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity. However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.
(BELG J HEMATOL 2017;8(2):53–65)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
G. Di Prinzio , J. Devreux , S. Lefebvre , S. Bailly MD, G. Verstraete MD, A. Bourgois , C. Pedreira , J-P. Defour PhD, A. Camboni MD, PhD, A. Marchandise , T. Pieters , M.C. Vekemans MD
BJH - volume 8, issue Abstract Book BHS, february 2017
J. Devreux , G. Di Prinzio , S. Bailly MD, S. Lefebvre , G. Verstraete MD, K. van Renterghem , A. Charlot , P. Saussoy MD, PhD, J-P. Defour PhD, N. Straetmans MD, PhD, X. Poiré MD, PhD, L. Michaux MD, PhD, M.C. Vekemans MD, V. Havelange MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
S. Bailly MD, M.C. Vekemans MD, B. Chatelain PharmD, M. André MD, PhD, T. Vander Borght , L. D’Hondt , L. Faugeras , G. Verstraete MD, J. Devreux , G. Di Prinzio , S. Lefevre
BJH - volume 8, issue Abstract Book BHS, february 2017
G. Verstraete MD, S. Lefevre , S. Bailly MD, G. Di Prinzio , J. Devreux , J-P. Defour PhD, P. D’Abadie , P. Van Eeckhout , F. Kino , C. Goemare , N. Lepage , L. Michaux MD, PhD, V. Havelange MD, PhD, E. Van den Neste MD, PhD, C. Lambert MD, PhD, L. Knoops MD, PhD, M.C. Vekemans MD, X. Poiré MD, PhD
BJH - volume 7, issue 1, february 2016
M.C. Vekemans MD
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic malignancies characterized by peripheral blood cytopenias, due to ineffective erythropoiesis and a risk for progression to acute myeloid leukemia (AML). Progress in this field aims to decrease the transfusion burden, delay progression to AML, improve the quality-of-life of patients and extend survival.
(BELG J HEMATOL 2016; 7(1): 20–4)
Read moreBJH - volume 7, issue Abstract Book BHS, january 2016
T. Tamakloe , N. Meité , S. Amat , P. Janssens , L. Marot , J-P. Defour PhD, P. Saussoy MD, PhD, H. Poirel MD, PhD, L. Michaux MD, PhD, E. Van den Neste MD, PhD, L. Knoops MD, PhD, V. Havelange MD, PhD, C. Lambert MD, PhD, X. Poiré MD, PhD, M.C. Vekemans MD
Top
